• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Pediatric glaucoma after cataract surgery

Article

The study found that pseudophakic children older at the time of surgery developed a glaucoma-related adverse event less frequently.

Image Credit: © nicoletaionescu - stock.adobe.com

The main outcomes were the cumulative incidence of glaucoma-related adverse events and baseline factors associated with risk of the adverse events. (nicoletaionescu / Adobe Stock)

Glaucoma specialists nationwide reported that glaucoma-related adverse events were common after cataract surgery in children, and children who were younger than 3 months at the time of surgery had an elevated risk of adverse events in aphakic eyes.1 Erick D. Bothun, MD, from the Department of Ophthalmology, Mayo Clinic, Rochester, MN, was the lead author of the study.

The researchers wanted to determine the cumulative incidence of glaucoma-related adverse events, ie, defined as glaucoma or glaucoma suspect, and factors associated with their risk during the first 5 years after lensectomy before children reach the age of 13 years.

The investigators used longitudinal registry data collected in this cohort study; the data were collected at enrollment and then annually for 5 years. Forty-five institutions and 16 community sites participated.

All children were 12 years old or younger and had completed at least 1 office visit after lensectomy from June 2012 to July 2015.

The main outcomes were the cumulative incidence of glaucoma-related adverse events and baseline factors associated with risk of the adverse events.

A total of 810 children (1,049 eyes) were included; 443 eyes of 321 children (mean age, 0.89 year) were aphakic after lensectomy, and 606 eyes of 489 children (mean age, 5.65 years) were pseudophakic.

The authors reported that the 5-year cumulative incidence of glaucoma-related adverse events was 29% (95% confidence interval [CI], 25%-34%) in the 443 aphakic eyes and 7% (95% CI, 5%-9%) in the 606 pseudophakic eyes.

Of the aphakic and pseudophakic eyes, 7% and 3%, respectively, were diagnosed as glaucoma suspects.

The authors elaborated on their findings. In the aphakic eyes, a higher risk for glaucoma-related adverse events was associated with 4 of 8 factors, ie, age younger than 3 months, abnormal anterior segment, intraoperative complications at time of lensectomy, and bilaterality. The 2 factors that were evaluated for the pseudophakic eyes, that is, the laterality and anterior vitrectomy, were not associated with a risk of glaucoma-related adverse events.

The study concluded that the children who were pseudophakic and who were older at the time of surgery, developed a glaucoma-related adverse event less frequently within 5 years of the lensectomy.

“The findings suggest that ongoing monitoring for the development of glaucoma is needed after lensectomy at any age,” investigators said.

Reference
1. Bothun ED, Repka MX, Kraker RT, et al. Incidence of glaucoma-related adverse events in the first 5 years after pediatric lensectomy. JAMA Ophthalmol. 2023;141:324-331;doi:10.1001/jamaophthalmol.2022.6413
Related Videos
Lorraine Provencher, MD, presenting slides
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Melissa Tawa, OD, FAAO
Deborah Ristvedt, DO, details CIME 2024 presentation on glaucoma management
David A. Berntsen, OD, PhD, FAAO, outlines his presentation on the BLINK 2 study presented at the 2024 ARVO meeting
Neda Shamie, MD, details the upcoming CIME 2024 meeting
© 2024 MJH Life Sciences

All rights reserved.